home / press / releases

Menu
  • Search all tables

releases: https://www.sanders.senate.gov/newsroom/must-read/drug-lobby-adds-100m-to-war-chest-ahead-of-pricing-battle

One row per release. Full-text search runs over title + body text.

Data license: MIT · Data source: dwillis/congress-press

This data as json

url title date year month party chamber state member_name bioguide_id domain scraper source date_source text has_text collected_at updated_at
https://www.sanders.senate.gov/newsroom/must-read/drug-lobby-adds-100m-to-war-chest-ahead-of-pricing-battle Drug lobby adds $100M to war chest ahead of pricing battle 2016-10-25 2016 2016-10 Independent House VT Bernard Sanders S000033 www.sanders.senate.gov     legacy Drug lobby adds $100M to war chest ahead of pricing battle By:  Sarah Karlin and Anna Palmer Tuesday, October 25, 2016 The pharmaceutical lobby is requiring member companies to fork over an additional $100 million per year as the industry gears up for a bruising post-election battle over drug prices, POLITICO has learned. PhRMA's decision to hike membership dues 50 percent will increase the trade group's considerable coffers to more than $300 million per year — a financial advantage it hasn’t enjoyed since 2009, when drug makers came out largely unscathed in Obamacare negotiations. PhRMA is bolstering its war chest as it gears up to spend hundreds of millions on ads pushing back against politicians from both parties who have attacked its members over pricing. Recent high-profile price increases of life-saving treatments, including EpiPens, have crystallized voter anger over drug costs. Both Hillary Clinton and Donald Trump have called for allowing the government to negotiate drug prices for Medicare beneficiaries and allowing drug importation from other countries. Recent polling shows a majority of Republican and Democratic voters favor both ideas. PhRMA’s board voted to raise dues at a meeting this summer, POLITICO reported in August, but it wasn’t clear by how much at the time. To help build its war chest, the board also voted to add new members, including Teva, the world’s largest generic drug manufacturer. Continue reading here. 1 2026-03-30T12:14:52Z 2026-03-30T12:14:52Z
Powered by Datasette · Queries took 0.769ms · Data license: MIT · Data source: dwillis/congress-press